Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.35 |
| ▸ | STS | P08842 | 3/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.34 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.34 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.34 |
| ▸ | KAT7 | O95251 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | PIM1 | P11309 | 2/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19631904 | 0.94 | STS (0.41) | PIK3CAEPHX2BRD4TGFBR1DNMT3A | |
| SCHEMBL29447360 | 0.94 | STS (0.41) | PIK3CAEPHX2BRD4TGFBR1DNMT3A | |
| SCHEMBL28519887 | 0.94 | STS (0.41) | PIK3CAEPHX2BRD4TGFBR1DNMT3A | |
| SCHEMBL19627746 | 0.94 | DNMT3A (0.36) | PIK3CAEPHX2BRD4TGFBR1DNMT3A | |
| SCHEMBL19627766 | 0.91 | EPHX2 (0.38) | PIK3CAEPHX2BRD4TGFBR1DNMT3A | |
| SCHEMBL29447352 | 0.88 | STS (0.40) | PIK3CAEPHX2BRD4TGFBR1DNMT3A | |
| SCHEMBL19613858 | 0.88 | STS (0.40) | PIK3CAEPHX2BRD4TGFBR1DNMT3A | |
| SCHEMBL19613857 | 0.88 | STS (0.40) | PIK3CAEPHX2BRD4TGFBR1DNMT3A | |
| SCHEMBL19627748 | 0.86 | SCN8A (0.43) | KAT6AKAT5 | |
| SCHEMBL19614216 | 0.86 | KMT2A (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | PIK3CA 2045/4885EPHX2 2484/4885BRD4 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.